NCT01465412View on ClinicalTrials.gov

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 10, 2011

Primary Completion Date

June 14, 2012

Study Completion Date

June 14, 2012

Conditions
Chronic Hepatic Impairment
Interventions
DRUG

Preladenant

After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01465412 - A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) | Biotech Hunter | Biotech Hunter